Ocera Therapeutics, Inc. (OCRX) - NASDAQ
  • Feb. 8, 2013, 8:36 AM

    Drugmaker Tranzyme (TZYM) +11.7% premarket on news it will explore a possible sale of the company, less than two years after it went public. Two mid-stage trials of its development drug for stomach paralysis recently were dropped due to lack of efficacy.

    | Feb. 8, 2013, 8:36 AM
Company Description
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002 ornithine phenylacetate. The OCR-002 is an ammonia scavenger which is used to treat hyperammonemia and associated hepatic encephalopathy in patients with liver... More
Sector: Healthcare
Industry: Biotechnology
Country: United States